Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Two Novel Variants in YARS2 Gene Are Responsible for an Extended MLASA Phenotype with Pancreatic Insufficiency

  • Carreño Gago, Lidia
  • Juarez-Flores, Diana Luz|||0000-0003-3615-7803
  • Grau, Josep M.|||0000-0001-7560-224X
  • Ramón, Javier|||0000-0002-0673-9338
  • Lozano, Ester|||0000-0002-6307-9807
  • Vila-Julià, Ferran
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Garrabou, Glòria|||0000-0001-8973-9933
  • García Arumí, Elena|||0000-0003-1848-005X
Pathogenic variants in the mitochondrial tyrosyl-tRNA synthetase gene (YARS2) were associated with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). However, patients can present mitochondrial myopathy, with exercise intolerance and muscle weakness, leading from mild to lethal phenotypes. Genes implicated in mtDNA replication were studied by Next Generation Sequencing (NGS) and whole exome sequence with the TruSeq Rapid Exome kit (Illumina, San Diego, CA, USA). Mitochondrial protein translation was studied following the Sasarman and Shoubridge protocol and oxygen consumption rates with Agilent Seahorse XF24 Analyzer Mitostress Test, (Agilent, Santa Clara, CA, USA). We report two siblings with two novel compound heterozygous pathogenic variants in YARS2 gene: a single nucleotide deletion in exon 1, c.314delG (p.(Gly105Alafs*4)), which creates a premature stop codon in the amino acid 109, and a single nucleotide change in exon 5 c.1391T.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Two Novel Variants in YARS2 Gene Are Responsible for an Extended MLASA Phenotype with Pancreatic Insufficiency

  • Carreño Gago, Lidia
  • Juárez-Flores, DL
  • Grau, Josep Maria
  • Ramon Pasías, Javier Francisco
  • Lozano, Ester
  • Vila Julià, Ferran
  • Martí Seves, Ramón
  • García Arumí, Elena
  • Garrabou, Gloria
Síndrome de Pearson; Aminocil-ARNt sintetasa mitocondrial; Nova variant patògena, Síndrome de Pearson; Aminocil-ARNt sintetasa mitocondrial; Nueva variante patógena, Pearson’s syndrome; Mitochondrial aminocyl-tRNA synthetase; Novel pathogenic variant, Pathogenic variants in the mitochondrial tyrosyl-tRNA synthetase gene (YARS2) were associated with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). However, patients can present mitochondrial myopathy, with exercise intolerance and muscle weakness, leading from mild to lethal phenotypes. Genes implicated in mtDNA replication were studied by Next Generation Sequencing (NGS) and whole exome sequence with the TruSeq Rapid Exome kit (Illumina, San Diego, CA, USA). Mitochondrial protein translation was studied following the Sasarman and Shoubridge protocol and oxygen consumption rates with Agilent Seahorse XF24 Analyzer Mitostress Test, (Agilent, Santa Clara, CA, USA). We report two siblings with two novel compound heterozygous pathogenic variants in YARS2 gene: a single nucleotide deletion in exon 1, c.314delG (p.(Gly105Alafs*4)), which creates a premature stop codon in the amino acid 109, and a single nucleotide change in exon 5 c.1391T>C (p.(Ile464Thr)), that cause a missense variant in amino acid 464. We demonstrate the pathogenicity of these new variants associated with reduced YARS2 mRNA transcript, reduced mitochondrial protein translation and dysfunctional organelle function. These pathogenic variants are responsible for late onset MLASA, herein accompanied by pancreatic insufficiency, observed in both brothers, clinically considered as Pearson’s syndrome. Molecular study of YARS2 gene should be considered in patients presenting Pearson’s syndrome characteristics and MLASA related phenotypes., This work was supported by the Spanish Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias and cofounded with ERDF funds (Grant No. FIS PI15/01428, FIS PMP15/00025 PI18/00498, PI19/01772, and the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Age-related metabolic changes limit efficacy of deoxynucleoside-based therapy in thymidine kinase 2-deficient mice

  • Blázquez-Bermejo, Cora
  • Molina-Granada, David|||0000-0002-8260-7775
  • Vila-Julià, Ferran
  • Jiménez-Heis, Daniel
  • Zhou, Xiaoshan
  • Torres-Torronteras, Javier|||0000-0002-6092-9458
  • Karlsson, Anna
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Cámara, Yolanda|||0000-0003-2458-6942
Thymidine kinase 2 (TK2) catalyses the phosphorylation of deoxythymidine (dThd) and deoxycytidine (dCtd) within mitochondria. TK2 deficiency leads to mtDNA depletion or accumulation of multiple deletions. In patients, TK2 mutations typically manifest as a rapidly progressive myopathy with infantile onset, leading to respiratory insufficiency and encephalopathy in the most severe clinical presentations. TK2-deficient mice develop the most severe form of the disease and die at average postnatal day 16. dThd+dCtd administration delayed disease progression and expanded lifespan of a knockin murine model of the disease. We daily administered TK2 knockout mice (Tk2 KO) from postnatal day 4 with equimolar doses of dThd+dCtd, dTMP+dCMP, dThd alone or dCtd alone. We monitored body weight and survival and studied different variables at 12 or 29 days of age. We determined metabolite levels in plasma and target tissues, mtDNA copy number in tissues, and the expression and activities of enzymes with a relevant role in mitochondrial dNTP anabolism or catabolism. dThd+dCtd treatment extended average lifespan of Tk2 KO mice from 16 to 34 days, attenuated growth retardation, and rescued mtDNA depletion in skeletal muscle and other target tissues of 12-day-old mice, except in brain. However, the treatment was ineffective in 29-day-old mice that still died prematurely. Bioavailability of dThd and dCtd markedly decreased during mouse development. Activity of enzymes catabolizing dThd and dCtd increased with age in small intestine. Conversely, the activity of the anabolic enzymes decreased in target tissues during mouse development. We also found that administration of dThd alone had the same impact on survival to that of dThd+dCtd, whereas dCtd alone had no influence on lifespan. dThd+dCtd treatment recruits alternative cytosolic salvage pathways for dNTP synthesis, suggesting that this therapy would be of benefit for any Tk2 mutation. dThd accounts for the therapeutic effect of the combined treatment in mice. During the first weeks after birth, mice experience marked tissue-specific metabolic regulations and ontogenetic changes in dNTP metabolism-related enzymes that limit therapeutic efficacy to early developmental stages. This study was funded by grants from the Spanish Ministry of Industry, Economy and Competitiveness, the Spanish Instituto de Salud Carlos III, the Fundación Inocente, Inocente, AFM Téléthon and the Generalitat de Catalunya. The disclosed funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy

  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Badosa, Carmen
  • Madruga-Garrido, Marcos
  • Martí, Itxaso|||0000-0003-0578-9568
  • Paradas, Carmen|||0000-0002-6917-2236
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Berardo, Andres
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Trifunov, Selena|||0000-0002-1807-9621
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Kalko, Susana G.|||0000-0002-6701-0233
  • Blázquez-Bermejo, Cora
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Mavillard, Fabiola|||0000-0002-1460-0483
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Montoya, Julio|||0000-0003-1770-6299
  • Ruiz-Pesini, Eduardo|||0000-0002-0269-7337
  • Villarroya, Joan
  • Montero, Raquel|||0000-0003-0609-5701
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Artuch, R.|||0000-0002-3422-9685
  • Hirano, Michio|||0000-0002-7070-7402
  • Nascimento, Andrés
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1-49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Late-onset thymidine kinase 2 deficiency, a review of 18 cases

  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Hernández-Laín, Aurelio
  • Rivas, Eloy
  • Hernández Voth, Ana
  • Sayas Catalán, Javier
  • Fernández-Torrón, Roberto
  • Fuiza-Luces, Carmen
  • García García, Jorge
  • Morís, Germán|||0000-0001-7608-2194
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Miralles, Francesc
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Caballero Sahelices, Concesa
  • Méndez Ferrer, Bosco
  • Martí, Ramon A.|||0000-0002-8273-9540
  • García Arumí, Elena|||0000-0003-1848-005X
  • Badosa, María Carmen
  • Esteban-Pérez, Jesús
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Encinar, Alberto Blazquez
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Hirano, Michio|||0000-0002-7070-7402
  • Martin, Miguel Ángel
  • Paradas, Carmen|||0000-0002-6917-2236
TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the 'myopathic form' of the mitochondrial depletion/multiple deletions syndrome, with a wide spectrum of severity. We describe 18 patients with mitochondrial myopathy due to mutations in the TK2 gene with absence of clinical symptoms until the age of 12. The mean age of onset was 31 years. The first symptom was muscle limb weakness in 10/18, eyelid ptosis in 6/18, and respiratory insufficiency in 2/18. All patients developed variable muscle weakness during the evolution of the disease. Half of patients presented difficulty in swallowing. All patients showed evidence of respiratory muscle weakness, with need for non-invasive Mechanical Ventilation in 12/18. Four patients had deceased, all of them due to respiratory insufficiency. We identified common radiological features in muscle magnetic resonance, where the most severely affected muscles were the gluteus maximus, semitendinosus and sartorius. On muscle biopsies typical signs of mitochondrial dysfunction were associated with dystrophic changes. All mutations identified were previously reported, being the most frequent the in-frame deletion p.Lys202del. All cases showed multiple mtDNA deletions but mtDNA depletion was present only in two patients. The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Collaborative model for diagnosis and treatment of very rare diseases, experience in Spain with thymidine kinase 2 deficiency

  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Madruga-Garrido, Marcos
  • Hirano, Michio|||0000-0002-7070-7402
  • Martí, Itxaso|||0000-0003-0578-9568
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Munell Casadesus, Francina|||0000-0001-8580-2819
  • Nascimento, Andrés
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Quan, Joanne
  • Sardina, Maria Dolores
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Paradas, Carmen|||0000-0002-6917-2236
Background: Mitochondrial diseases are difficult to diagnose and treat. Recent advances in genetic diagnostics and more effective treatment options can improve patient diagnosis and prognosis, but patients with mitochondrial disease typically experience delays in diagnosis and treatment. Here, we describe a unique collaborative practice model among physicians and scientists in Spain focused on identifying TK2 deficiency (TK2d), an ultra-rare mitochondrial DNA depletion and deletions syndrome. Main Body: This collaboration spans research and clinical care, including laboratory scientists, adult and pediatric neuromuscular clinicians, geneticists, and pathologists, and has resulted in diagnosis and consolidation of care for patients with TK2d. The incidence of TK2d is not known; however, the first clinical cases of TK2d were reported in 2001, and only ~ 107 unique cases had been reported as of 2018. This unique collaboration in Spain has led to the diagnosis of more than 30 patients with genetically confirmed TK2d across different regions of the country. Research affiliate centers have led investigative treatment with nucleosides based on understanding of TK2d clinical manifestations and disease mechanisms, which resulted in successful treatment of a TK2d mouse model with nucleotide therapy in 2010. Only 1 year later, this collaboration enabled rapid adoption of treatment with pyrimidine nucleotides (and later, nucleosides) under compassionate use. Success in TK2d diagnosis and treatment in Spain is attributable to two important factors: Spain's fully public national healthcare system, and the designation in 2015 of major National Reference Centers for Neuromuscular Disorders (CSURs). CSUR networking and dissemination facilitated development of a collaborative care network for TK2d disease, wherein participants share information and protocols to request approval from the Ministry of Health to initiate nucleoside therapy. Data have recently been collected in a retrospective study conducted under a Good Clinical Practice-compliant protocol to support development of a new therapeutic approach for TK2d, a progressive disease with no approved therapies. Conclusions: The Spanish experience in diagnosis and treatment of TK2d is a model for the diagnosis and development of new treatments for very rare diseases within an existing healthcare system.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Muscle MRI characteristic pattern for late-onset TK2 deficiency diagnosis

  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Fernández-Torrón, Roberto
  • Moore, Ursula|||0000-0002-0643-5596
  • de Fuenmayor-Fernández de la Hoz, Carlos Pablo
  • Vélez-Gómez, Beatriz|||0000-0001-5796-5872
  • Cabezas, Juan Antonio
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • González Mera, Laura
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • García-García, Jorge
  • Morís, Germán|||0000-0001-7608-2194
  • León Hernández, Juan Carlos
  • Muelas, Nuria|||0000-0002-2349-7481
  • Servian-Morilla, Emilia
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Paradas, Carmen|||0000-0002-6917-2236
Background and objective: TK2 deficiency (TK2d) is a rare mitochondrial disorder that manifests predominantly as a progressive myopathy with a broad spectrum of severity and age of onset. The rate of progression is variable, and the prognosis is poor due to early and severe respiratory involvement. Early and accurate diagnosis is particularly important since a specific treatment is under development. This study aims to evaluate the diagnostic value of lower limb muscle MRI in adult patients with TK2d. Methods: We studied a cohort of 45 genetically confirmed patients with mitochondrial myopathy (16 with mutations in TK2, 9 with mutations in other nuclear genes involved in mitochondrial DNA [mtDNA] synthesis or maintenance, 10 with single mtDNA deletions, and 10 with point mtDNA mutations) to analyze the imaging pattern of fat replacement in lower limb muscles. We compared the identified pattern in patients with TK2d with the MRI pattern of other non-mitochondrial genetic myopathies that share similar clinical characteristics. Results: We found a consistent lower limb muscle MRI pattern in patients with TK2d characterized by involvement of the gluteus maximus, gastrocnemius medialis, and sartorius muscles. The identified pattern in TK2 patients differs from the known radiological involvement of other resembling muscle dystrophies that share clinical features. Conclusions: By analyzing the largest cohort of muscle MRI from patients with mitochondrial myopathies studied to date, we identified a characteristic and specific radiological pattern of muscle involvement in patients with TK2d that could be useful to speed up its diagnosis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Two Novel Variants in YARS2 Gene Are Responsible for an Extended MLASA Phenotype with Pancreatic Insufficiency

  • Carreño Gago, Lidia
  • Juárez-Flores, DL
  • Grau, Josep Maria
  • Ramon Pasías, Javier Francisco
  • Lozano, Ester
  • Vila Julià, Ferran
  • Martí Seves, Ramón
  • García Arumí, Elena
  • Garrabou, Gloria
Síndrome de Pearson; Aminocil-ARNt sintetasa mitocondrial; Nova variant patògena, Síndrome de Pearson; Aminocil-ARNt sintetasa mitocondrial; Nueva variante patógena, Pearson’s syndrome; Mitochondrial aminocyl-tRNA synthetase; Novel pathogenic variant, Pathogenic variants in the mitochondrial tyrosyl-tRNA synthetase gene (YARS2) were associated with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). However, patients can present mitochondrial myopathy, with exercise intolerance and muscle weakness, leading from mild to lethal phenotypes. Genes implicated in mtDNA replication were studied by Next Generation Sequencing (NGS) and whole exome sequence with the TruSeq Rapid Exome kit (Illumina, San Diego, CA, USA). Mitochondrial protein translation was studied following the Sasarman and Shoubridge protocol and oxygen consumption rates with Agilent Seahorse XF24 Analyzer Mitostress Test, (Agilent, Santa Clara, CA, USA). We report two siblings with two novel compound heterozygous pathogenic variants in YARS2 gene: a single nucleotide deletion in exon 1, c.314delG (p.(Gly105Alafs*4)), which creates a premature stop codon in the amino acid 109, and a single nucleotide change in exon 5 c.1391T>C (p.(Ile464Thr)), that cause a missense variant in amino acid 464. We demonstrate the pathogenicity of these new variants associated with reduced YARS2 mRNA transcript, reduced mitochondrial protein translation and dysfunctional organelle function. These pathogenic variants are responsible for late onset MLASA, herein accompanied by pancreatic insufficiency, observed in both brothers, clinically considered as Pearson’s syndrome. Molecular study of YARS2 gene should be considered in patients presenting Pearson’s syndrome characteristics and MLASA related phenotypes., This work was supported by the Spanish Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias and cofounded with ERDF funds (Grant No. FIS PI15/01428, FIS PMP15/00025 PI18/00498, PI19/01772, and the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER).